The collaboration builds on the work UCB and Microsoft have
already embarked on around COVID-19. As part of the COVID Moonshot project,
UCB’s medicinal and computational chemists contributed compound designs to this
worldwide open-science project to create an orally bioavailable anti-viral for
COVID-19 - with the most potent series of compounds coming from UCB designs.
This combination of cutting-edge science, computing power,
and AI algorithms aims to significantly accelerate the iteration cycles
required to explore a vast chemical space to test many hypotheses and identify
more effective molecules. The collaboration plans to extend this model and
identify other areas where computing power, AI, and science can accelerate the
development of life changing therapies for people living with severe diseases
in immunology and neurology. The work will augment UCB’s scientists, subject
matter experts, and research partners across every part of the drug discovery
and delivery value chain by harnessing diverse research information and AI
models alongside human expertise and creativity.
“We are delighted to be collaborating with Microsoft to
uncover new insights to better understand a patient’s condition, as well as the
science, and to enable an enhanced patient experience,” said Jean-Christophe
Tellier, CEO of UCB. “By amplifying the power of scientific innovation through
digital transformation, we hope to have a better understanding of what makes a
patient’s journey unique so that we can provide personalized and differentiated
medicine in a sustainable way.”
UCB and Microsoft will explore how to combine diverse
research data sets with four strategic objectives in mind, allowing UCB to:
- Improve a patient’s overall journey
- Increase the impact of a treatment through a deeper understanding of the biological causes of the disease
- Systematically provide better research data-driven insights to enable the faster discovery of therapeutic molecules
- Accelerate clinical development timelines
“Together, UCB and Microsoft are taking on some of
healthcare’s greatest challenges to find connected, innovative ways to create
better experiences, insights, and more personal and more effective care. With
the deep knowledge that UCB offers in drug discovery and the knowledge of human
biology, together with Microsoft’s unmatched expertise in computer science and
AI, we have a unique opportunity to reinvent the way new medicines are
created.” says Jean-Philippe Courtois, EVP and President, Microsoft Global
Sales, Marketing & Operations.
UCB, Brussels, Belgium ( www.ucb.com ) is a global
biopharmaceutical company focused on the discovery and development of
innovative medicines and solutions to transform the lives of people living with
severe diseases of the immune system or of the central nervous system. With
more than 7 500 people in approximately 40 countries, UCB generated revenue of
€ 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB).
0 comments:
Post a Comment